Compare CAE & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | CORT |
|---|---|---|
| Founded | 1947 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.7B |
| IPO Year | 2002 | 2001 |
| Metric | CAE | CORT |
|---|---|---|
| Price | $25.18 | $95.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $33.33 | ★ $96.50 |
| AVG Volume (30 Days) | 522.2K | ★ 1.1M |
| Earning Date | 05-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $4.97 | $26.08 |
| Revenue Next Year | N/A | $26.98 |
| P/E Ratio | $35.13 | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $22.76 | $28.66 |
| 52 Week High | $34.24 | $97.05 |
| Indicator | CAE | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 63.30 |
| Support Level | $24.77 | $76.41 |
| Resistance Level | $26.18 | N/A |
| Average True Range (ATR) | 0.62 | 4.17 |
| MACD | -0.03 | -0.36 |
| Stochastic Oscillator | 41.50 | 81.02 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: i) Civil Aviation: Provides comprehensive training solutions for flight, cabin, maintenance, ground personnel and air traffic controllers in commercial, business and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training and crew sourcing services, as well as airline operations digital solutions; and ii) Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.